Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.
Philip Noel NewsomeSven FrancqueStephen HarrisonVlad RatziuLuc Van GaalSalvatore CalannaMorten HansenMartin LinderArun J SanyalPublished in: Alimentary pharmacology & therapeutics (2019)
Semaglutide significantly reduced ALT and hsCRP in clinical trials in subjects with obesity and/or type 2 diabetes.